UBS Group’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,627
| Closed | -$5.18K | – | 10582 |
|
|
2025
Q2 | $5.18K | Sell |
4,627
-36,482
| -89% | -$44.6K | ﹤0.01% | 9200 |
|
|
2025
Q1 | $47.3K | Buy |
41,109
+30,611
| +292% | +$56.9K | ﹤0.01% | 7640 |
|
|
2024
Q4 | $64.1K | Buy |
10,498
+3,294
| +46% | +$39.1K | ﹤0.01% | 7146 |
|
|
2024
Q3 | $119K | Sell |
7,204
-1,203
| -14% | -$13.2K | ﹤0.01% | 6234 |
|
|
2024
Q2 | $57.8K | Sell |
8,407
-4,924
| -37% | -$42.1K | ﹤0.01% | 6582 |
|
|
2024
Q1 | $129K | Buy |
13,331
+131
| +1% | +$1.52K | ﹤0.01% | 6106 |
|
|
2023
Q4 | $110K | Buy |
13,200
+6,199
| +89% | +$36K | ﹤0.01% | 6122 |
|
|
2023
Q3 | $58.5K | Sell |
7,001
-955
| -12% | -$8.1K | ﹤0.01% | 6199 |
|
|
2023
Q2 | $73.4K | Buy |
7,956
+3,148
| +65% | +$35.3K | ﹤0.01% | 6235 |
|
|
2023
Q1 | $66.1K | Buy |
4,808
+850
| +21% | +$17.6K | ﹤0.01% | 6235 |
|
|
2022
Q4 | $67.3K | Buy |
3,958
+3,718
| +1,549% | +$74.4K | ﹤0.01% | 6484 |
|
|
2022
Q3 | $5K | Sell |
240
-596
| -71% | -$12K | ﹤0.01% | 9199 |
|
|
2022
Q2 | $15K | Sell |
836
-257
| -24% | -$4.58K | ﹤0.01% | 7294 |
|
|
2022
Q1 | $29K | Sell |
1,093
-51,556
| -98% | -$960K | ﹤0.01% | 7029 |
|
|
2021
Q4 | $1.54M | Buy |
52,649
+17,908
| +52% | +$890K | ﹤0.01% | 3975 |
|
|
2021
Q3 | $2.28M | Buy |
34,741
+30,739
| +768% | +$2.35M | ﹤0.01% | 3469 |
|
|
2021
Q2 | $333K | Sell |
4,002
-12,259
| -75% | -$908K | ﹤0.01% | 5013 |
|
|
2021
Q1 | $1.25M | Buy |
16,261
+16,087
| +9,245% | +$1.46M | ﹤0.01% | 4033 |
|
|
2020
Q4 | $15K | Sell |
174
-5,391
| -97% | -$379K | ﹤0.01% | 7161 |
|
|
2020
Q3 | $411K | Buy |
5,565
+5,230
| +1,561% | +$310K | ﹤0.01% | 4336 |
|
|
2020
Q2 | $24K | Sell |
335
-2,667
| -89% | -$162K | ﹤0.01% | 6430 |
|
|
2020
Q1 | $169K | Sell |
3,002
-4,157
| -58% | -$182K | ﹤0.01% | 4856 |
|
|
2019
Q4 | $273K | Buy |
+7,159
| New | +$180K | ﹤0.01% | 5367 |
|
Other funds holding IGMS
UBS Group's IGMS Position: Q3 2025 in Review
UBS Group sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 4,627 shares — an estimated $5.18K sold.
UBS Group first reported a position in IGMS in Q4 2019 and held it in 23 quarters. The position peaked at $2.28M in Q3 2021. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- UBS Group reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- UBS Group sold 4,627 IGM Biosciences shares in Q3 2025, an estimated $5.18K.
- UBS Group first reported a position in IGM Biosciences in Q4 2019 and held it in 23 quarters.
- UBS Group's IGM Biosciences position peaked at $2.28M in Q3 2021.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.